Estados Unidos · Bolsa y Finanzas · Morningstar

Vivacta Bio and Grit Bio Announce FDA Orphan Drug Designation for In Vivo CAR-T Therapy GT801 in Autoimmune Hemolytic Anemia

Publicado por Morningstar · Estados Unidos hace 21 h

SHANGHAI, Oct. 17, 2026 /PRNewswire/ -- Vivacta Biotechnology (Shanghai) Co., Ltd. ("Vivacta Bio"), a company spun out of the in vivo CAR-T platform of Beijing Grit…

Leer el artículo completo en Morningstar Inicie sesión para guardar

MediaNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.morningstar.com)

Vivacta Bio and Grit Bio Announce FDA Orphan Drug Designation for In Vivo CAR-T Therapy GT801 in Autoimmune Hemolytic Anemia

También te puede interesar

Replit is no longer working with Anthropic, CEO says

My 2 friends and I had babies within 3 weeks of each other after 25 years of friendship. Our group chat became a lifeline.

Weak Links Start to Show in A.I. Borrowing

Alberta has the world’s fourth-largest oil reserves and sends 90% of its crude exports to the U.S. — It will vote on a first step to leaving Canada

Bulls vs. Bears: Is CoreWeave the canary in AI coalmine?

Crypto Super PAC Fairshake Pours Millions More Into Defeating Sherrod Brown

Vivacta Bio and Grit Bio Announce FDA Orphan Drug Designation for In Vivo CAR-T Therapy GT801 in Autoimmune Hemolytic Anemia

Compartir

También te puede interesar

Replit is no longer working with Anthropic, CEO says

My 2 friends and I had babies within 3 weeks of each other after 25 years of friendship. Our group chat became a lifeline.

Weak Links Start to Show in A.I. Borrowing

Alberta has the world’s fourth-largest oil reserves and sends 90% of its crude exports to the U.S. — It will vote on a first step to leaving Canada

Bulls vs. Bears: Is CoreWeave the canary in AI coalmine?

Crypto Super PAC Fairshake Pours Millions More Into Defeating Sherrod Brown